However, as the PALB2 c.1592delT founder mutation, with a frequency of roughly 1% also in Finnish breast cancer cases unselected for their family history of disease, increases the risk of breast cancer in a way comparable to that of BRCA2[21], targeted clinical testing for c.1592delT seems appropriate. Here, PALB2 is linked to breast carcinoma.